🇺🇸 FDA
Patent

US 10876114

Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53

granted A61KA61K31/56A61K31/57

Quick answer

US patent 10876114 (Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53) held by BIOMARIN TECHNOLOGIES B.V. expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOMARIN TECHNOLOGIES B.V.
Grant date
Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/56, A61K31/57, A61K31/573, A61K31/58